106 related articles for article (PubMed ID: 29382394)
1. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
[TBL] [Abstract][Full Text] [Related]
2. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
[TBL] [Abstract][Full Text] [Related]
3. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
[TBL] [Abstract][Full Text] [Related]
4. Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating
Zhang X; Wang Y; Li S; Xie F; Yi H
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0154123. PubMed ID: 38319075
[TBL] [Abstract][Full Text] [Related]
5. Removal of common antimicrobial agents by sustained low-efficiency dialysis.
Hudson JQ; Hilgers MN; Gosmanova EO
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0157923. PubMed ID: 38349160
[TBL] [Abstract][Full Text] [Related]
6. Changes of PK/PD of Meropenem in patients with abdominal septic shock and exploration of clinical rational administration plan: a prospective exploratory study.
Wang Y; Li H; Wang D; Li Y; Shen Y; Fu Y; Li Y; Gao M; Zhang D
Sci Rep; 2024 May; 14(1):10173. PubMed ID: 38702351
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?
Andersen MG; Thorsted A; Storgaard M; Kristoffersson AN; Friberg LE; Öbrink-Hansen K
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507062
[TBL] [Abstract][Full Text] [Related]
8. Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis.
Liu Q; Li S; Xie F
Int J Antimicrob Agents; 2023 Oct; 62(4):106949. PubMed ID: 37574029
[TBL] [Abstract][Full Text] [Related]
9. Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis.
Avedissian SN; Skochko SM; Le J; Hingtgen S; Harvey H; Capparelli EV; Richardson A; Momper J; Mak RH; Neely M; Bradley JS
J Pediatr Pharmacol Ther; 2020; 25(5):413-422. PubMed ID: 32641911
[TBL] [Abstract][Full Text] [Related]
10. Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infection.
Murínová I; Švidrnoch M; Gucký T; Řezáč D; Hlaváč J; Slanař O; Šíma M
Eur J Hosp Pharm; 2024 Apr; 31(3):253-258. PubMed ID: 36307183
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients.
Alsultan A; Aldawsari MR; Alturaiq NK; Syed SA; Alsubai A; Kurdee Z; Alsubaie S; Alqahtani S; Abouelkheir M
Pediatr Neonatol; 2024 Jan; ():. PubMed ID: 38218717
[TBL] [Abstract][Full Text] [Related]
12. Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.
Pokorná P; Michaličková D; Tibboel D; Berner J
Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786147
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Therapeutic Target Attainment of Meropenem in Pediatric Post-Liver Transplant Patients: Extended vs Intermittent Infusion.
Morales Junior R; Juodinis VD; Telles JP; Romano P; Duarte NJC; De Souza DC; Santos SRCJ
Transplant Proc; 2023 Dec; 55(10):2456-2461. PubMed ID: 37923571
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of prophylactic cefoxitin in elective bariatric surgery patients: a prospective monocentric study.
Novy E; Liu X; Hernández-Mitre MP; Belveyre T; Scala-Bertola J; Roberts JA; Parker SL
Anaesth Crit Care Pain Med; 2024 Jun; 43(3):101376. PubMed ID: 38494157
[TBL] [Abstract][Full Text] [Related]
15. Individual meropenem epithelial lining fluid and plasma PK/PD target attainment.
Rohani R; Yarnold PR; Scheetz MH; Neely MN; Kang M; Donnelly HK; Dedicatoria K; Nozick SH; Medernach RL; Hauser AR; Ozer EA; Diaz E; Misharin AV; Wunderink RG; Rhodes NJ
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0072723. PubMed ID: 37975660
[TBL] [Abstract][Full Text] [Related]
16. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation.
Minichmayr IK; Friberg LE
Int J Antimicrob Agents; 2024 Jun; ():107236. PubMed ID: 38851463
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling of Unbound Meropenem in Patients Undergoing Continuous Renal Replacement Therapy: An Observational Cohort Study.
Oda K; Jono H; Kamohara H; Saito H
Ther Drug Monit; 2024 May; ():. PubMed ID: 38758632
[TBL] [Abstract][Full Text] [Related]
18. Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with
Nakashima H; Miyazaki M; Kuwamura T; Oda K; Haga Y; Imakyure O
Antibiotics (Basel); 2024 Feb; 13(3):. PubMed ID: 38534654
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetics and dosing simulations of total and unbound temocillin in the plasma and CSF of neurocritically ill patients with external ventricular drain-related cerebral ventriculitis.
Ngougni Pokem P; Liu X; Parker SL; Verroken A; Collienne C; Finet P; Wijnant GJ; Laterre PF; Roberts JA; Van Bambeke F; Wittebole X
J Antimicrob Chemother; 2024 Feb; 79(2):429-442. PubMed ID: 38153240
[TBL] [Abstract][Full Text] [Related]
20. Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections.
Fornari C; Arrieta A; Bradley JS; Tout M; Magalhaes P; Auriol FK; Borella E; Piana C; Pasqua OD; Vallespir BP; Mazzei P; Bokesch PM; Hoover R; Capriati A; Habboubi N
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38925918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
